Why then are they pushed so hard in patients who are especially vulnerable? The answer relates more to the religion than to the science of vaccines.
You have just had a heart transplant. You do not want to reject your new heart. Why, then, get a flu vaccine? Why get a swine flu vaccine with ASO3 adjuvant? Because your ignorant doctor advised you strongly to do so, after all the hype.
And what happened? You were 26 times more likely to have a severe, acute cellular rejection episode.
Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients.
Schaffer SA, Husain S, Delgado DH, Kavanaugh L, Ross HJ. Am J Transplant. 2011 Dec;11(12):2751-4.
Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada. allan.schaffer@utoronto.ca
Abstract
During the H1N1 influenza virus pandemic, vaccination of high risk groups including solid-organ transplant recipients was advised. A retrospective case control study of 60 heart transplant patients, 15 having received the H1N1 virus antigen and ASO3 adjuvant vaccine (GlaxoSmithKline, Mississauga, ON, Canada) within 21 days and 45 having not been vaccinated, all undergoing routine surveillance endmyocardial biopsies, was performed. The overall rate of cellular rejection (all grades) was not statistically different between groups; however, acute cellular rejection, ≥grade 2 (1990 ISHLT criteria), was more frequent among those having recently vaccinated (control: 1/45 vs. 6/15, p = 0.001). On multivariate analysis, the only risk factor found to be associated with acute cellular rejection was recent H1N1 viral antigen and adjuvant vaccination (OR 26.5: 95% CI 02.59-270.5). Vaccine adjuvants increase host response to vaccine antigens by immune upregulation potentially increasing risk of rejection in solid-organ transplant recipients. The potential hazard of vaccination this study raises must be weighed with the clear benefit vaccination has proven to be.
No comments:
Post a Comment